Miyoshi, Jun
Ozaki, Ryo
Yonezawa, Hiromi
Mori, Hideaki
Kawamura, Naohiro
Matsuura, Minoru
Hisamatsu, Tadakazu http://orcid.org/0000-0002-1178-3536
Funding for this research was provided by:
The Japan Sciences Research Grant for Research on Intractable Diseases
Article History
Received: 10 November 2021
Accepted: 26 December 2021
First Online: 24 January 2022
Declarations
:
: Minoru Matsuura received consulting and lecture fees from Janssen Pharmaceutical K.K.; and received a scholarship grant from Nippon Kayaku Co., Ltd. Tadakazu Hisamatsu received consulting and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.; and received research grants from Alfresa Pharma Co., Ltd., EA pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, AbbVie GK, JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi-Sankyo, Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Mochida Pharmaceutical Co., Ltd. Jun Miyoshi, Ryo Ozaki, Hiromi Yonezawa, Hideaki Mori, and Naohiro Kawamura have no conflict of interest.